10 Best Debt-Free S&P 500 Stocks to Buy Now

8. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

On May 22, 2026, Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) announced that the European Medicines Agency accepted for review under Accelerated Assessment the Marketing Authorization Application for Otarmeni, an in vivo adeno-associated virus vector-based gene therapy for biallelic OTOF variant-associated hearing loss. Otarmeni, formerly known as DB-OTO, previously received Orphan Designation from the EMA. If approved, Otarmeni would become the first gene therapy for OTOF-related hearing loss in the European Union. The application is supported by data from the pivotal CHORD trial, where 24 participants received a single dose of Otarmeni through intracochlear infusion.

On May 19, 2026, Canaccord analyst John Newman lowered the firm’s price target on Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) to $875 from $1,057 and maintained a Buy rating on the shares. Newman updated the model after the Phase 3 study of fianlimab+cemiplimab versus pembrolizumab failed to hit statistical significance on the primary endpoint of progression-free survival, calling it a surprising and disappointing event.

Wolfe Research analyst Alexandria Hammond also lowered the firm’s price target on Regeneron to $860 from $900 and maintained an Outperform rating. Hammond said the company’s LAG-3 trial missed its primary endpoint, while noting that commercial execution will be important and that second-half 2026 catalysts may be underappreciated.

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) discovers, develops, manufactures, and commercializes medicines to treat various diseases worldwide.